📖
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Rocio Garcia-Carbonero, Maria San-Roman-Gil, Belen Llana, Paula Jimenez-Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo-García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez-Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García-Álvarez, Amparo García-Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Science & Mathematics Published 2025 Verification Pending

Overview & Synopsis

Background: Everolimus is the only approved therapy for patients with advanced neuroendocrine tumors (NET) of lung and thymus and new treatment options are urgently needed. Expression of somatostatin receptor 2 (SSTR2) is frequently seen in functional imaging in lung-NETs opening the opportunity to treat SSTR2 positive patients with radioligand therapies (RLT). Retrospective data suggest a potential meaningful benefit of RLT directed to SSTR2 in lung-NET patients. Methods: The LEVEL trial is a randomized, open-label, phase III international trial of 177Lu-edotreotide versus everolimus in patients with progressive, locally advanced or metastatic, and well/moderately differentiated NETs of lung (typical/atypical) or thymic origin. Patients could be treatment-naïve or have progressed (PD) on somatostatin analogues or ≤ 2 additional systemic treatments. Prior RLT or mTOR inhibitors are not permitted. Eligible patients are randomly assigned 3:2 to 6 cycles of 177Lu-edotreotide (total administered activity 7.5 ± 0.7 GBq / cycle) or to oral everolimus 10 mg once daily until PD or unacceptable toxicity. Only patients with positivity in somatostatin receptor imaging will be included. CT or MRI scans are performed every 12 weeks until PD. Blood samples are analyzed at baseline, at 1st tumor assessment, and at PD for pharmacodynamic endpoints. Archival tumor tissue samples will be analyzed for ancillary studies. The primary endpoint is progression-free survival (PFS) according to RECIST v1.1 based on local investigator assessment. Secondary endpoints include overall survival, overall response rate, safety, and quality of life (EORTC QLQ-C30). The expected sample size is 120 patients to demonstrate statistical significant risk reduction of 46.4% (HR = 0.536) in PFS with the experimental treatment using an overall 5% two-sided alpha error with 80% power. An interim PFS analysis was included using the Lan-DeMets with O'Brian-Fleming-like boundaries. Discussion: The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Author / Organization Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Rocio Garcia-Carbonero, Maria San-Roman-Gil, Belen Llana, Paula Jimenez-Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo-García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez-Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García-Álvarez, Amparo García-Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2025
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-243512
Original Source Link Visit Source Page on hal.science »